| Ytd | -98.43% | |
| 1y | -98.43% |
| Open | 0.37 | Prev Close | 0.38 | Low | 0.36 | High | 0.39 | Mkt Cap | 4.79M |
| Vol | 65.82K | Avg Vol | 90.86K | EPS | -0.75 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.49 | 200-d Avg | 1.46 | 1yr Est | 0.00 |
Gainers XORTX Therapeutics (NASDAQ:XRTX) shares moved upwards by 7.8% to $1.52 during Friday's
Gainers Onconetix (NASDAQ:ONCO) stock increased by 10.3% to $1.14 during Friday's after-market
Gainers Lakewood-Amedex (NASDAQ:LABT) stock rose 38.0% to $3.45 during Monday's after-market se
20/20 Biolabs (NASDAQ:AIDX) reported quarterly losses of $(0.26) per share which missed the analyst
20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20 Biolabs" or the "Company"), an early marke
Under the terms of the Agreement, during the 120-day period beginning on the date of the Agreement,
Shares of Super Micro Computer Inc (NASDAQ: SMCI) rose after reporting record backlog of $60B+ in or
Tower Semiconductor (TSEM) jumped 4.7% in pre-market trading after announcing a multi-year supply ag
https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/
Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Rev
20/20 Biolabs (NASDAQ:AIDX) reported quarterly losses of $(0.28) per share which missed the analyst
20/20 BioLabs, Inc. ("20/20") (NASDAQ:AIDX), an early market entrant in cutting-edge, AI pow
Maxim Group analyst Michael Okunewitch initiates coverage on 20/20 Biolabs (NASDAQ:AIDX) with a B
Joint Release Expands 20/20 BioLabs' Testing Solutions Across Evexia's Network of ~40,000 Fu
20/20 Biolabs (NASDAQ:AIDX) reported quarterly losses of $(0.76) per share. This is a 34.48 percent
State-Funded Screening Initiative Highlights Growing Public Sector Support for Innovative Cancer Det
Shares of 20/20 Biolabs, Inc. (NASDAQ: AIDX) are trading lower Tuesday after the company announced t
Inflammatory Biomarker Tracking Predicted to Enhance Response to 3-D Bio-Printed TherapiesExpands On
20/20 BioLabs (NASDAQ:AIDX), an early market entrant in cutting-edge, AI powered laboratory-based bl